What a pharma journal advertisement must carry in India
A journal advertisement that aims to inform a prescribing decision carries the five items of UCPMP 2024 Clause 3.2. Two further clauses matter most for this format. Clause 3.3 says promotional material must not be designed to disguise its real nature. Journal material that a company pays for, secures or arranges must not resemble the editorial matter. Clause 3.4 applies that to such material naming a company product by brand, whatever the editorial control.
In short
- Clause 3.2's five items, plus two clauses that matter most for journals.
- Clause 3.3: journal material a company pays for, secures or arranges must not resemble editorial matter.
- UCPMP 2024 governs pharmaceutical promotion. Its Clause 3.2 sets the minimum information for material whose purpose is to give persons qualified to prescribe enough information for a prescribing decision. Section 2 governs claims and comparisons, and Clause 2.1 sets the evidence basis for claims of usefulness.
- Space pressure does not reduce the requirement. It reduces what the advertisement can responsibly claim.
The rule is one clause, and it is about purpose
Clause 3.2 opens with a condition, and the condition is about purpose rather than format. "Where the purpose of the promotional material is to provide persons qualified to prescribe with sufficient information upon which to reach a decision for prescription or for use". If that describes the piece, all five items below apply to it, whatever the piece is called internally.
| Feature | Clause | Basis | What the Code says |
|---|---|---|---|
| Company identification | UCPMP 2024, Clause 3.2(i) | Code (UCPMP 2024) | The relevant drug, the name and address of the holder of authorization for the drug (or the business name and address of the part of the business responsible for placing the drug on the market). Required whether or not the piece is left behind. The manufacturing licence number is a label requirement under the labelling rules of the Drugs and Cosmetics Rules 1945. Clause 3.2 does not require it on promotional material. |
| Generic name | UCPMP 2024, Clause 3.2(ii) | Code (UCPMP 2024) | The name of the drug, along with a list of active ingredients, using the generic name, placed immediately adjacent to the most prominent display of the name of the drug. Adjacency is the requirement. Size is not. The Code sets no relationship between the generic name and the brand name in point size. |
| Dosage and administration | UCPMP 2024, Clause 3.2(iii) | Code (UCPMP 2024) | Recommended dosage, method of use, and where not obvious, its method of administration. |
| Safety information | UCPMP 2024, Clause 3.2(iv) | Code (UCPMP 2024) | Adverse reactions, warnings, precautions for use and relevant contraindications for the use of the product. Read with Clause 1.3, which requires information to be balanced and not misleading. That is where fair balance actually comes from. |
| Availability statement and date | UCPMP 2024, Clause 3.2(v) | Code (UCPMP 2024) | A statement that additional information is available on request, and the date on which the above particulars were generated or last updated. Easy to add and easy to forget. A piece reprinted for years with no date on the particulars does not meet this. |
The Code requires the information to be given 'legibly' and to be 'an integral part of the promotional material'. It sets no point size. Any minimum your team works to, such as 8pt, is an internal MLR standard. It is not a legal threshold. Be clear about that in review, so nobody defends a house rule as though it were law.
Clause 3.2 sets the minimum information. Other clauses of the Code apply too. Clause 3.8 asks for the date of printing or of the last review 'wherever appropriate', for example on technical and other informative material. That date is different from the Clause 3.2(v) date. Clause 3.6 bars the names or photographs of health professionals in promotional material. The general points and the clauses on claims and comparisons, in Sections 1 and 2, also apply.
The clauses that bite hardest here
Clause 3.3 states: 'Promotional material such as mailings and journal advertisements must not be designed to disguise their real nature'. It adds a rule for material a company 'pays for, or otherwise secures or arranges' in journals. Such material 'must not resemble the editorial matter'. Clause 3.4 extends Clause 3.3 to all such journal material that names a company product by brand. It applies 'irrespective of the editorial control of the material published'. Advertorial formats are where this bites.
Which instruments govern a journal advertisement
UCPMP 2024 governs pharmaceutical promotion. Its Clause 3.2 sets the minimum information for material whose purpose is to give persons qualified to prescribe enough information for a prescribing decision. Section 2 governs claims and comparisons. Clause 2.1 says: 'Claims for the usefulness of a drug must be based on up-to-date evaluation of all available evidence'.
The Drugs and Magic Remedies (Objectionable Advertisements) Act 1954 is not limited to advertising to the public. For doctor material, the relevant saving is Section 14(c), and it is narrow. It covers only an advertisement 'sent confidentially in the manner prescribed under section 16 only to a registered medical practitioner'. A page bought in a journal is not obviously sent confidentially. An advertisement may link a drug to a condition in the Act's Schedule, such as diabetes or high blood pressure. If so, check it against the Act. Whether a placement meets the Section 14(c) condition is a question for your regulatory team.
The Drugs and Cosmetics Rules 1945, add a licence condition for Schedule H, H1 and X drugs. No advertisement of those drugs may be made without the previous sanction of the Central Government. Rules 74(p) and 78(q) are examples. The text sets no audience limit. How it applies to a journal read by prescribers is a question for your regulatory team.
Space is the constraint that causes the failures
A journal page is bought, and everything in Clause 3.2 competes with the creative for it. The clause requires the information to be legible and integral. So when it will not fit, the resolution is to reduce what the advertisement claims. Cutting the information that supports the claim does not resolve it.
Frequently asked questions
Is a journal advertisement governed by the ASCI Code?
UCPMP 2024 governs pharmaceutical promotion. Section 2 governs claims and comparisons. Clause 3.2 sets the minimum information for material whose purpose is to give persons qualified to prescribe enough information for a prescribing decision. Whether the ASCI Code also reaches a particular journal placement is a question for your regulatory team. This page does not rely on it.
Can a journal advertisement be laid out like an article?
No. Clause 3.3 requires that promotional material not be designed to disguise its real nature. Journal material that a company pays for, secures or arranges must also not resemble the editorial matter of the journal.
Does a journal ad need a separate reference to the full prescribing information?
Clause 3.2(v) requires a statement that additional information is available on request, together with the date the particulars were generated or last updated. That is the Code's form of it.
Check it before MLR does
Collateral Advisor reviews each page you upload across five dimensions: medical, compliance, visual design, copywriting and best practice.
Free trial, no card needed. MarketingSense is a pre-MLR advisory assistant. Your medical, legal and regulatory team still makes the final call.